A Japanese study found high remission and continuation rates, plus non-inferior trough levels, after patients with IBD were switched to the infliximab biosimilar CT-P13.

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

Sandoz's Edward Li explains how biosimilar denosumab pricing could reshape cost-effectiveness, payer access, and gaps in ...

Patients with neovascular age-related macular degeneration (nAMD) who transitioned from off-label bevacizumab to a biosimilar and then to a branded anti-VEGF agent had longer injection intervals ...

A Japanese study found high remission and continuation rates, plus non-inferior trough levels, after patients with IBD were switched to the infliximab biosimilar CT-P13.

A study found no direct trial evidence for natalizumab or its biosimilar in MS and found limited cost-effectiveness vs most ...

Most pediatric and young adult patients with IBD maintained stable disease activity and laboratory markers after switching ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...